We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
126
Apogee Therapeutics
APGE
$10.1B
$105K 0.08%
2,425
-6,753
-74% -$257K
CRDO icon
127
CALL
Credo Technology Group
CRDO
$37.8B
$94.5K 0.07%
+140
New +$8.16K
PHAT icon
128
Phathom Pharmaceuticals
PHAT
$873M
$90.3K 0.07%
+9,421
New +$52.1K
AVR
129
Anteris Technologies
AVR
$823M
$88.4K 0.07%
23,317
– –
NUVL icon
130
Nuvalent
NUVL
$87.7K 0.07%
+1,150
New +$84.1K
ALEC icon
131
Alector
ALEC
$167M
$85.5K 0.06%
61,096
-43,831
-42% -$54.9K
ATYR
132
CALL
aTyr Pharma
ATYR
$50M
$81.6K 0.06%
297
+171
+136% +$673
SPY icon
133
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$74.6K 0.06%
+120
New +$68.6K
PRQR icon
134
ProQR Therapeutics
PRQR
$240M
$74K 0.05%
36,280
-11,503
-24% -$18.7K
GOSS icon
135
CALL
Gossamer Bio
GOSS
$83.2M
$73.6K 0.05%
1,929
– –
CRSP icon
136
CALL
CRISPR Therapeutics
CRSP
$4.71B
$73.4K 0.05%
258
– –
PGY icon
137
CALL
Pagaya Technologies
PGY
$1.43B
$71.6K 0.05%
+250
New +$3.56K
REPL icon
138
Replimune Group
REPL
$859M
$69.6K 0.05%
7,492
-9,651
-56% -$84.2K
ZYME icon
139
CALL
Zymeworks
ZYME
$1.78B
$64.5K 0.05%
418
– –
AFRM icon
140
CALL
Affirm
AFRM
$25.5B
$64.4K 0.05%
+66
New +$3.42K
AGIO icon
141
CALL
Agios Pharmaceuticals
AGIO
$2.36B
$63.5K 0.05%
316
+6
+2% +$182
RXRX icon
142
CALL
Recursion Pharmaceuticals
RXRX
$1.56B
$61.8K 0.05%
1,606
– –
RKT icon
143
CALL
Rocket Companies
RKT
$41.1B
$57.4K 0.04%
262
+214
+446% +$2.78K
SMMT icon
144
CALL
Summit Therapeutics
SMMT
$10.7B
$55.8K 0.04%
175
+115
+192% +$2.62K
TNGX icon
145
CALL
Tango Therapeutics
TNGX
$4.65B
$55.4K 0.04%
+461
New +$1.14K
NBIS
146
CALL
Nebius Group N.V.
NBIS
$45.1B
$53.6K 0.04%
+140
New +$4.82K
ALT icon
147
CALL
Altimmune
ALT
$558M
$53.4K 0.04%
2,910
+1,949
+203% +$10.5K
UBER icon
148
CALL
Uber
UBER
$147B
$46.1K 0.03%
+160
New +$13.2K
JAZZ icon
149
CALL
Jazz Pharmaceuticals
JAZZ
$15.5B
$42.8K 0.03%
115
-48
-29% -$5.21K
ACAD icon
150
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
$40.6K 0.03%
+204
New +$3.79K
4 5
6
7 8

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.